吉西他滨联合奈达铂治疗复发或难治性侵袭性非霍奇金淋巴瘤  

Gemcitabine with nedaplatinregimen for the patients with relapsed or refractory aggressive non-Hodgkin's lymphoma

作　　者：金永东[1] 卢进[1] 梅开[1] 

机构地区：[1]四川省肿瘤医院头颈腹盆内科,成都610041

出　　处：《中国肿瘤临床与康复》2013年第4期332-334,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨吉西他滨联合奈达铂方案治疗难治或复发性非霍奇金淋巴瘤的近期疗效和不良反应。方法 38例难治或复发性非霍奇金淋巴瘤采用吉西他滨联合奈达铂方案进行解救化疗,吉西他滨1000mg/m2,静脉滴注,第1,8天;奈达铂100 mg/m2,静脉滴注,第1天。21天为1个周期。结果所有患者均完成>2个周期的吉西他滨联合奈达铂方案化疗,总有效率为60.5%,完全缓解率为37.8%,部分缓解率为23.7%。主要不良反应为骨髓抑制及胃肠道反应,经治疗均恢复。结论吉西他滨联合奈达铂方案作为治疗难治或复发性非霍奇金淋巴瘤的解救方案,近期疗效确切,不良反应可耐受,远期疗效有待观察。Objective To evaluate the efficancy and adverse events of gemcitabine plus nedaplatin regimen on replased or refractory non-Hodgkin＇ s lymphoma（NHL）. Methods A total of 38 patients with replased or refractory non-Hodgkin＇ s lymphoma accepted gemcitabine plus nedaplatin regimen for over than 2 cycles, gemcitabine plus nedaplatin regimen： gemcitabine 1000mg/m2） ivgtt dl, d8;nedaplatin 100 rag/ m2ivgtt d1,21d as a cycle. The efficancy,the changes of KPS score, survivaltime and adverse events were e- valuated. Results Of the 38 patients, the response rate was 61.8%. The response rates of complete re- sponse （CR） and partial response （PR） were 68. 4% and 60%, respectively;The major side effects were bone marrow depression and gastrointestinal reactions. Conclusions gemcitabine plus nedaplatin regimen is a safe and effective salvage regimen for the patients with repalsed and refractory NHL.

关 键 词：非霍奇金淋巴瘤 吉西他滨 奈达铂 药物疗法 

分 类 号：R733.1[医药卫生—肿瘤]